Is it Worth Adding Boston Scientific Stock to Your Portfolio Now?

Core Insights - Boston Scientific's MedSurg segment is experiencing robust growth, particularly in endoscopy, neuromodulation, and urology, with promising long-term prospects for WATCHMAN devices [1][5][8] - The company's stock has outperformed the industry and S&P 500, with a 33.6% increase over the past year [2] - Strategic acquisitions have significantly contributed to revenue growth, with recent buyouts adding 400 basis points to Q1 sales and driving 18.2% organic revenue growth [6][9] MedSurg Segment Performance - The Endoscopy business is gaining market share due to strong growth in endoluminal surgery and single-use imaging franchises, alongside the AXIOS platform [3] - Urology market share is expanding globally, driven by successful product launches like the TENACIO pump and the LithoVue portfolio [4] - Neuromodulation is also seeing growth, particularly in pain and brain businesses, with expectations for improved growth in deep brain stimulation by 2025 [4] WATCHMAN Device Growth - The WATCHMAN device is gaining momentum as a leading non-pharmacologic alternative to oral anti-coagulants, with a 24% year-over-year sales increase in Q1 2025 [5][8] - The next-generation WATCHMAN FLX and FLX Pro are capturing significant market share [5] Strategic Acquisitions - Recent acquisitions, including Bolt Medical and Cortex, have added valuable products to Boston Scientific's portfolio [6] - The acquisition of Axonics in Q4 2024 has also contributed positively to sales growth [9] Financial Performance - The company has consistently beaten earnings estimates, with an average surprise of 8.79% over the last four quarters [2] - The Zacks Consensus Estimate for 2025 earnings per share is $2.91, with revenues expected to rise by 16.4% to $19.50 billion [11] Currency Exposure - Boston Scientific faces risks from currency fluctuations, with 40% of sales coming from international markets, which could impact revenues by 50 basis points in 2025 [10]